Abstract 1009P
Background
Advanced hepatocellular carcinoma (HCC) is a highly lethal disease with limited treatment options. The use of first-line (1L) systemic therapies showcase improved overall survival and quality of life. This study aimed to compare the objective response rate (ORR) of various systemic therapies for advanced HCC in 1L setting using a network meta-analysis.
Methods
A systematic literature review (SLR) and network meta-analysis (NMA) of randomized controlled trials (RCTs) was conducted to assess the efficacy of 1L systemic therapies for advanced HCC. Multiple databases, including PubMed, Embase, and the Cochrane Library were searched for relevant studies. The primary outcome of interest was the ORR of each therapy compared to placebo. The results were obtained for both fixed and random-effect models to estimate each therapy's relative risk (RR) and 95% credible intervals (CrI).
Results
A total of 12 RCTs met the inclusion criteria. The combination therapy of sintilimab + IBI305 had the highest ORR, with an RR of 13.6 (95% CrI: 3.69, 55.67) using fixed-effect and RR of 14.13 (95% CrI: 0.82, 120.1) using random-effect models. SUCRA values ranged from 0.075 for placebo to 0.761 for sintilimab + IBI30. SUCRA rankings were generally better for combination therapies followed by mono-therapies and placebo.
Conclusions
The NMA revealed that the combination therapies had the highest ORR among the systemic therapies in the 1L setting. The SUCRA values confirmed the high probability of these treatments ranking higher in terms of ORR and can be used to support treatment decision-making in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
G. Kaur, B. Singh, S. Attri, A. Sharma, P. Rai, S. Pandey: Financial Interests, Personal, Full or part-time Employment: Pharmacoevidence.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18